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Several beneﬁcial effects of splenectomy on the liver integrity have been recently reported by both
experimental and clinical studies. However, the effects of splenectomy on hepatic functional reserve and
structural damage in patients with chronic hepatitis C (CHC) were not studied by objective evidence. The
aim of this study was to assess the effect of splenectomy on hepatic functional reserve and structural
damage in patients with CHC by non-invasive serum markers. The study involved 22 patients with
histopathological diagnosis of CHC undergoing splenectomy for treatment of associated hypersplenism.
The hepatic functional reserve and structural damage markers were assessed before and after splenec-
tomy surgery on the 2nd and 60th postoperative days by aspartate aminotransferase to alanine
aminotransferase (AST/ALT ratio), AST to platelet ratio index (APRI) and serum levels of gamma-glutamyl
transferase (GGT), hyaluronic acid (HA), type IV collagen (CIV) and tissue inhibitor of metalloproteinase-1
(TIMP-1). After splenectomy, the levels of serum HA showed a signiﬁcant decrease in relation to the
preoperative values both in PO-1 (mean pre-splenectomy: 272  88.6 versus 185  77.4 ng/ml; P ¼ 0.01)
and PO-2 (169  58.1 ng/ml; 0.017). The levels of type IV collagen showed a signiﬁcant decrease in relation
to the preoperative values both in PO-1 (mean pre-splenectomy: 208  134 versus 125  100 ng/ml;
P ¼ 0.01) and PO-2 (121  74.7 ng/ml; P ¼ 0.02). Serum levels of TIMP-1 also showed a signiﬁcant de-
crease in relation to the preoperative values both in PO-1 (mean pre-splenectomy: 764  571 versus
261  195 ng/ml; P ¼ 0.006) and PO-2 (149  110.1 ng/ml; P ¼ 0.004). There was no signiﬁcant difference
between PO-1 and PO-2 mean values for each of those serummarkers. This study found that splenectomy
induced a reduction of biochemical markers of liver functional reserve and ﬁbrosis in patients with
chronic hepatitis C which reﬂect a change in the processes involved in of liver ﬁbrosis. However, it cannot
be concluded whether this reﬂects a change in the rate of its progression or a prevention of further
ﬁbrosis.
 2008 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Several beneﬁcial effects of splenectomy on the liver integrity
have been recently reported by both experimental and clinical
studies. Splenectomy was found to have a preventive role against
experimentally induced liver ﬁbrosis in rats by an endotoxin or
CCl4.1,2 Also, it was reported that splenectomy enhanced liver
regeneration in cirrhotic rat model.3 Splenectomy was found to be
beneﬁcial in patients with chronic hepatitis C (CHC) and hyper-
splenism to raise the platelet count so that; medical therapy by
pegylated interferon and ribavirin can be given.4 The addition of
splenectomy to resection surgery for hepatocellular carcinoma onþ2 01 2728 1418.
.A. Elsebae).
ciates Ltd. Published by Elsevier Lttop of CHC was found to improve anti-tumor immune function,
speed the recovery of liver physiological role and delay of the
progression of liver cirrhosis.5,6 Moreover, it was reported that
serum HCV RNA titers were found lower in the splenectomized
patients with CHC than in cirrhotic controls.7 However, the afore-
mentioned effects of splenectomy on the liver structural damage
and functional reserve in patients with CHC were not studied by
objective evidences. Non-invasive serum markers as an alternative
to liver biopsy have recently become an essential investigation to
evaluate the hepatic functional reserve, inﬂammatory grade and
ﬁbrotic stage of liver disease in those patients; which are easy
reproducible and accurate.8–13 Aim of this study is to assess the
effect of splenectomy on hepatic functional reserve and structural
damage in patients with CHC by non-invasive serum markers
namely; serum hyaluronic acid (HA), aspartate aminotransferase to
alanine aminotransferase (AST/ALT) ratio, AST to platelet ratiod. All rights reserved.
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type IV collagen (CIV) and serum tissue inhibitor of metal-
loproteinase-1 (TIMP-1), before and after splenectomy surgery.
2. Material and methods
2.1. Patients and study design
The study involved 22 consecutive cirrhotic patients with
histopathological diagnosis of chronic viral hepatitis C infection
(CHC) who underwent elective splenectomy surgery. The in-
dications of splenectomy surgery were the treatment of associated
hypersplenism, thrombocytopenia and/or bleeding esophageal
varices. Selection criteria of the patients involved that none of them
had history of habitual alcohol consumption or exhibited clinical, or
histological evidence of other chronic liver diseases as well as, none
had been receiving anti-viral or immmunomodulatory therapy.
The hepatic functional reserve and structural damage markers
were assessed before and after splenectomy surgery on the 2nd and
60th postoperative days by aspartate aminotransferase to alanine
aminotransferase (AST/ALT ratio), AST to platelet ratio index (APRI)
and serum levels of gamma-glutamyl transferase (GGT), hyaluronic
acid (HA), type IV collagen (CIV) and tissue inhibitor of metal-
loproteinase-1 (TIMP-1). All those parameters were assessed in 20
normal healthy controls for comparisonwith preoperative values of
patients in the study. Comparison between pre- and postoperative
levels of the markers was a statistically analyzed. Preoperative
serum levels of hyaluronic acid, type IV collagen and TIMP-I were
correlated to preoperative serum levels liver enzymes and platelet
counts.
2.2. Methods
All patients were subjected to full clinical examination, routine
laboratory assessment by full blood picture, liver and kidney
functions tests, abdominal sonography and upper GIT endoscopy.
Then, the patients were classiﬁed according to Child–Pugh
classiﬁcation. Testing of seropositivity for markers of viral hepatitis
B (HBs Ag & HBc Ab) was done by (ELISA kit of Boehringer
Mannheim) and viral hepatitis C (HCV antibodies by Murex version
III ELISA & HCV mRNA by PCR). Patients with viral hepatitis B
infection were excluded.
A written informed consent was obtained from every patient
involved in the study. The study and collection of serum was
approved by the Local Ethical Committee of TBRI.
Splenectomy was performed in all patients. Additional gastro-
esophageal devascularization was undertaken when there was
history of bleeding esophageal varices.
2.3. Biochemical markers assessment
Serum bilirubin, AST, ALT, GGT, and albumin were all measured
on fresh serum within 36 h of collection. Other special analyses
(HA, CIV and TIMP-1) will be performed in sera stored frozen at
20 C:
(1) Serum hyaluronic acid (HA) essay: quantitative determination
of serum HA was performed by using an enzyme-linked
binding protein assay kit from (Corgenix, Inc., CO). In this assay
system, a capture molecule known as hyaluronic acid binding
protein (HABP) is used.
(2) Type IV collagen (CIV) essay: serum level of CIV was measured
by a single step sandwich enzyme immunoassay kit using two
monoclonal antibodies directed against type IV collagen (Bio-
trin, Ireland).(3) Tissue inhibitor of metalloproteinase-1 (TIMP-1) essay: serum
level of TIMP-1 was quantitated by a single step sandwich
enzyme immunoassay kit using two monoclonal antibodies
directed against TIMP-1 from (Chemicon International, Inc.,
CA).2.4. Statistical analysis
Results were expressed as means  standard deviation.
Comparison of differences between patients in the study and nor-
mal healthy controls at baseline were statistically analyzed using
Student’s t-test. Comparison between pre- and postoperative levels
of serummarkers was performed by paired Student’s t-test. P-value
<0.05 was considered signiﬁcant. Data were plotted by Whisker
box plot chart (Microsoft Excel, 2003 worksheet). Preoperative
serum levels of hyaluronic acid, type IV collagen and TIMP-I were
correlated to preoperative serum levels liver enzymes and platelet
count by the rank correlation test.
3. Results
3.1. Clinical data of the patients
Fourteen patients were men, while eight were women. Their
mean agewas 46.8 (range 41–53) years. All patients presented with
splenomegaly and hematological criteria for hypersplenism. Upper
gastrointestinal endoscopic examination revealed esophagus vari-
ces in seven patients, while the history of upper gastrointestinal
bleeding was positive in three of them. Preoperatively, 18 patients
were classiﬁed as Child–Pugh grade A, and four patients as grade B.
Abdominal ultrasonography excluded the presence of focal hepatic
lesions in all patients. All patients had detectable hepatitis C virus
mRNA at the time of evaluation.
Postoperative course of all patients was uneventful with no
major complications and without mortality. Patients were
discharged for follow up at the outpatient clinic. None of the
patients received anti-viral medical therapy during the follow up
period. The liver function status of the patients was assessed
2 months following splenectomy; 20 patients were classiﬁed
according to Child–Pugh as grade A and two patients as grade B.
That is to say; Child–Pugh class of patients didn’t become worse
following splenectomy, it was even improved from class-B to class-
A in two patients.
3.2. Blood counts
Preoperative mean values of hemoglobin, total leucocytic count
and platelet count were lower than normal. The mean values of
platelet count and total leucocytic count (TLC) were signiﬁcantly
elevated after splenectomy more than preoperative values both at
the 2nd and the 60th postoperative days (Table 1).
3.3. Kidney function tests
Preoperative and postoperative blood urea and serum creatinine
levels were within normal limits for all patients. This signiﬁes that
there was no renal impairment in any of the patients which might
affect the results of the assessed parameters.
3.4. Liver function tests
Mean value of serum albumin was not of a statistically signiﬁ-
cant difference before surgery and at the 2nd postoperative day
(P ¼ 0.608). However, those results may be biased by the intensive
parenteral infusions of human albumin and fresh frozen plasma
Table 1
Hematology parameters before and after splenectomy
Variable/timing Before
splenectomy
After splenectomy
(postoperative days)
2nd 60th
Hb (g/dL) 9.83  0.32
(9.2–10.3)
11.33  0.23
(11.0–12.6)
11.02  0.2
(10. 6–14.0)
Total leucocytic
count  109/L
3.3  0.12
(3.3–3.8)
8.2  0.1
(4.3–10. 2)*
6.1  0.4
(4.0–8.2)**
Platelet count  109/L 45.9  16.2
(37.0–67.0)
232  23.7
(232–260)*
202  23.7
(210–240)**
Values are expressed as mean (SD) and ranges. * ¼ signiﬁcant at P < 0.01,
** ¼ signiﬁcant at P < 0.05 versus pre-splenectomy.
Table 3
AST/ALT ratios & APRI and serum GGT before and after splenectomy
Variable/timing Before
splenectomy
After splenectomy
(postoperative days)
Normal controls
2nd 60th
GGT (U/L) 92.3  87.6
(82–196)*
46.4  50.2
(32–104)**
50.24 31
(41–97)**
11  0.2
(5–25)
AST/ALT ratio 2.4  1.0
(1.1–3.4)*
2. 2  0.86
(1.3–3.2)
1.42  0.86
(1.2–2.4)*
0.77 0.92
(0.94–1)
AST/platelets ratio index 1.96  0.12
(1.1–2.0)*
0.13  0.05
(0.1–0.2)***
0.17  0.1
(0.1–0.2)***
0. 05  0. 01
(0.04–0.08)
Values are expressed as mean (SD) and ranges. * ¼ signiﬁcant at P < 0.00 versus
normal controls, ** ¼ signiﬁcant at P < 0.01, *** ¼ signiﬁcant at P < 0.05 versus
pre-splenectomy.
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surgery. Mean value of serum albumin on the 60th postoperative
day was signiﬁcantly higher than preoperative value. Mean values
of serum AST and ALT were higher in the preoperative than the 2nd
postoperative day but not signiﬁcantly while, at the 60th post-
operative day they were signiﬁcantly lower than preoperative
values (Table 2).
3.5. AST/ALT ratios & AST/platelets ratio index (APRI) and
serum gamma-glutamyl transferase (GGT)
The preoperative mean values of AST/ALT ratios, APRI and serum
GGT were signiﬁcantly higher than that in 20 normal healthy
controls (P < 0.00) (Table 3). The mean value of AST/ALT ratios at
the 2nd postoperative day exhibited non-signiﬁcant difference
from preoperative value while, it was lower than preoperative
value by a statistically signiﬁcant difference on the 60th day post-
operative day (P ¼ 0.003), while the mean value of APRI decreased
by a statistically signiﬁcant level at both the 2nd and 60th day after
splenectomy (P ¼ 0.039 & 0.044), and themean value of serum GGT
decreased by a statistically signiﬁcant level at both the 2nd and
60th day after splenectomy (P ¼ 0.006 & 0.004) (Table 3).
3.6. Serum HA levels
Preoperative serum HA levels were found >86 ng/ml in all
patients. The mean value of serum HA was signiﬁcantly higher
preoperatively than that for 20 normal healthy controls. After
splenectomy, the mean value of serum HA showed a statistically
signiﬁcant decrease in relation to the preoperative values both at
the 2nd and 60th day postoperatively (P ¼ 0.01 and 0.017
respectively). There was no signiﬁcant difference between the
mean values of the postoperative 2nd and 60th day serum levels of
HA (Table 4, Fig. 1).Table 2
Liver function parameters before and after splenectomy
Serum variables/timing Before
splenectomy
After splenectomy
(postoperative days)
2nd 60th
Bilirubin (mg/dL) 0.82  0.11
(0.8–1.2)
0.93  0.11
(0.2–1.8)
1.02  0.31
(0.8–1.0)
Albumin (g/L) 3.15  0.71
(2.6–3.5)
3.05  0.52
(2.8–3.8)
3.78  1.01
(3.5–4.2)*
AST (U/L) 78.9  59.27
(17–138)
57.7  31.34
(37–96)
37.7  11. 7
(13–42)*
ALT (U/L) 80.1  10.9
(12–88)
50.1  21.6
(31–76)
26.1  12.6
(13–36)*
Alkaline phosphatase (U/L) 54  3
(44 – 57)
53  6
(43 –59)
43  9
(41 –52)
Values are expressed as mean (  SD) and ranges. * ¼ signiﬁcant at P < 0.05 versus
pre-splenectomy.3.7. Type IV collagen (CIV) & TIMP-1serum levels
The preoperative mean values of CIV and TIMP-1 were signiﬁ-
cantly higher than that in 20 normal healthy controls (P < 0.00)
(Table 4). After splenectomy, the mean value of type IV collagen
showed a signiﬁcant decrease in relation to the preoperative values
both at the 2nd (P ¼ 0.01) and 60th postoperative day (P ¼ 0.02).
The mean value of TIMP-1 also showed a signiﬁcant decrease in
relation to the preoperative values both in the 2nd (P ¼ 0.006) and
60th day (P ¼ 0.004) postoperatively. There was no signiﬁcant dif-
ference between the mean values of the postoperative 2nd and
60th day serum levels of CIV and TIMP-1 (Table 4, Figs. 2 and 3).
The preoperative serum levels of hyaluronic acid, type IV col-
lagen were signiﬁcantly correlated with serum levels of alanine
aminotransferase (ALT) and platelet count (P < 0.05). Otherwise,
there was no signiﬁcant correlation between the preoperative se-
rum levels of hyaluronic acid, type IV collagen or TIMP-1 and the
preoperative values of liver enzymes (Table 5).
4. Discussion
Chronic viral hepatitis C (CHC) is a major health problem among
Egyptians.14 It is the most common cause of liver cirrhosis in our
country and splenectomy is the most popular surgical procedure
for treatment of associated hypersplenism and esophageal varices
when endoscopic sclerotherapy fails. Identiﬁcation of the presence
of signiﬁcant liver ﬁbrosis by a liver biopsy is an important part of
the diagnostic work-up of patients with this disease. However, liver
biopsy is an invasive test which is afﬂicted with a high degree of
sampling error and amorbidity rate of 0.3–0.6% and amortality rate
up to 0.05%.15 In clinical practice repeating liver biopsy procedure
simply to follow up the evolution of the disease over time is not20
70
120
170
220
270
320
370
420
470
 Preop.
 
Se
ru
m
 h
ya
lu
ro
ni
c a
ci
d 
(n
g/m
l)
Post -1. Post-2.
Fig. 1. Mean and box plot of serum hyaluronic acid level preoperatively (preop.), two
days (Post-1) and 60 days (Post-2) after splenectomy.
Table 4
Biochemical markers of liver functional reserve and ﬁbrosis before
and after splenectomy
Variable/timing Before
splenectomy
After splenectomy
(postoperative days)
Normal
controls
2nd 60th
Hyaluronic acid (ng/ml) 272  88.6
(152–447)***
185  77.4
(84–329)**
169  58.1
(93–271)**
29.9  10.3
(8–47)
Type IV collagen (ng/ml) 208  134
(97–471)***
125  100
(53–298)**
121  74.7
(73–255)**
54.4  13.6
(37–71)
TIMP–1 (ng/ml) 764.  571
(48–1482)***
261  195
(12–504)*
149  110
(9–268)*
175  20.5
(35–197)
Values are expressed as mean (SD) and ranges. * ¼ signiﬁcant at P < 0.00,
** ¼ signiﬁcant at P < 0.05 versus before splenectomy values, *** ¼ signiﬁcant at
P < 0.00 before splenectomy versus normal controls values.
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Fig. 3. Mean and box plot of serum tissue inhibitor of metalloproteinase-1 level pre-
operatively (preop.), two days (Post-1) and 60 days (Post-2) after splenectomy.
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ﬁbrosis developed as an alternative to liver biopsy. Two classes of
serum biomarkers can be differentiated. Class I markers are those,
which reﬂect ECM turnover such as hyaluronan, collagen peptides
and tissue inhibitor of metalloproteinases. Class II biomarkers are
based on algorithmic evaluation of commonly observed functional
alterations of the liver which are mostly routine laboratory tests
such as AST/ALT ratio AST to platelet ratio index (APRI). In clinical
practice, the use of combinations of simple, reproducible, and
inexpensive parameters has proved predictive of ﬁbrosis grade in
patients with CHC.9,10,16–20
Hyaluronic acid (HA) is a polysaccharide synthesized by hepatic
stellate cells, which are the dominant proﬁbrogenic cell type in
liver, and speciﬁcally degraded and metabolized by sinusoidal
endothelial cells in the liver. Elevation of serum HA occurs when
liver cirrhosis is established due reduction of its degradation be-
cause of hepatic sinusoids capillarization. Serum hyaluronic acid
was reported as a useful marker of liver ﬁbrosis in CHC.21,22 HA half-
life time is 2–5 min that makes it also, a sensitive marker of liver
functional reserve.11 For example, serial measurement of serum HA
was found valuable in early detection of liver failure after major
hepatectomy.23,24 Type IV collagen (CIV) is a large component of the
extracellular matrix (ECM) which is excessively deposited in
ﬁbrosis process. Metalloproteinases are a group of enzymes
secreted by hepatic stellate cells. They are involved in the degra-
dation of ECM and speciﬁcally inhibited by tissue inhibitor of
metalloproteinases (TIMPs). Immunoassay techniques allow the
measurement of type IV collagen (CIV) and tissue inhibitor of
metalloproteinase-1 (TIMP-1) in the serum. The magnitude of
elevation of those markers in sera of patients with CHC has been
demonstrated to be indicative of the ﬁbrotic stage as assessed by
liver biopsy.25–3120
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Fig. 2. Mean and box plot of serum collagen type-4 level preoperatively (preop.), two
days (Post-1) and 60 days (Post-2) after splenectomy.Role of the spleen in liver ﬁbrosis was studied experimentally in
several reports.5,6,33 An interesting report by Akahoshi et al. (2002),
suggested that inhibitory cytokines originate from the spleen are
involved in liver ﬁbrosis. Spleen-derived transforming growth
factor-beta 1 (TGF-beta 1) plays a crucial role in the matrix
production during liver ﬁbrosis and removal of the spleen would
negate that inhibitory factor and hinder the healing of liver
cirrhosis by inhibiting the regeneration of the damaged liver.33
There is some evidence that splenectomy can positively affect
Kupffer cell functions in the liver, and protects against viral
infection.34 A compensatory increase in the activity of NK cells in
splenectomized patients inﬂuence the immune mediators and
virus load of cirrhotic patients with HCV infection.35
Review of literature by Medline search from 1990 to 2008, no
clinical study was found that speciﬁcally addressed the effect of
splenectomy on liver ﬁbrosis in patients with CHC. Splenectomy in
hepatic schistosomiasis patients was found to be associated with
a decrease in the levels of serum markers of liver ﬁbrosis CIV and
TIMP-1. It was suggested that the spleen plays a role in the extra-
cellular matrix production, and therefore may contribute to liver
ﬁbrosis in that disease.32 In this study, the levels of biomarkers of
the hepatic functional reserve and ﬁbrosis namely; serum hyalur-
onic acid (HA), AST/ALT ratio, AST to platelet ratio index (APRI),
serum gamma-glutamyl transferase (GGT), serum type IV collagen
(CIV) and serum tissue inhibitor of metalloproteinase-1, (TIMP-1),
were elevated in all of patients with CHC before splenectomy
compared to healthy controls. Splenectomy in those patients has
been proved to be associated with a decrease in the levels of those
markers and that effect persisted from the 2nd to 60th post-
operative day after the operation. The explanation of the un-
derlyingmechanisms remains to be elucidated. It was reported that
splenectomy diminishes virus burden in cirrhotic patients with
HCV infection at least in part, through augmentation of natural
killer cell activity.7 However, no correlation was found between
HCV viral load and the severity of liver disease and the HCV RNATable 5
preoperative serum levels of hyaluronic acid, type IV collagen and TIMP-1
in correlation to liver enzymes and platelet count
Variables HA CIV TIMP-1
r-value P-value r-value P-value r-value P-value
AST 0.5758 0.088 0.5273 0.123 0.1685 0.641
ALT 0.7395 0.017* 0.6635 0.039* 0.234 0.515
Alkaline
phosphatase
0.4273 0.218 0.3303 0.348 0.3251 0.36
Platelet count 0.1879 0.036* 0.6242 0.046* 0.2119 0.5571
* ¼ statistically signiﬁcant at P < 0.05.
M.M.A. Elsebae, N.B. Abu-Zekri / International Journal of Surgery 6 (2008) 362–366366titer has no statistical relationship with the histological activity
index score.36 The severity of liver disease judged by the values of
serum albumin, bilirubin, and ALT and AST levels were reported to
be independent of serum levels of hepatitis C virus.37 Thus; the
results of our study conﬁrms that splenectomy would be beneﬁcial
concerning the liver structural status and functional reserve in the
patients with chronic hepatitis C. That fact should be considered in
the surgeon’s mind, planning for indicated splenectomy surgery in
those patients. However, the mechanism remains speculative;
whether it is due to reduction of virus burden, amelioration of
portal hypertension, improvement of the immunologic proﬁle
following splenectomy or if it is due to removal of a spleen factor
that inhibits liver regeneration.
5. Conclusion
This study found that splenectomy induced a reduction of bio-
chemical markers of liver functional reserve and ﬁbrosis in patients
with chronic hepatitis C which reﬂect a change in the processes
involved in liver ﬁbrosis. However, it cannot be concluded whether
this reﬂects a change in the rate of its progression or a prevention of
further ﬁbrosis.Conﬂict of interest
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